{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:15:03Z","timestamp":1790630103915,"version":"4.1.0"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["24326"],"award-info":[{"award-number":["24326"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["28988"],"award-info":[{"award-number":["28988"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["355923"],"award-info":[{"award-number":["355923"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.neuropharm.2019.05.007","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T07:45:51Z","timestamp":1557387951000},"page":"107630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Antipsychotic-evoked dopamine supersensitivity"],"prefix":"10.1016","volume":"163","author":[{"given":"Alice","family":"Servonnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-1910","authenticated-orcid":false,"given":"Anne-No\u00ebl","family":"Samaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.05.007_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1748-1716.1983.tb07363.x","article-title":"Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites","volume":"119","author":"Agnati","year":"1983","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib2","first-page":"1327","article-title":"Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment","volume":"14","author":"Amato","year":"2011","journal-title":"Int. J. Neuropsychopharmacol.\/Off. Sci. J. Coll. Int. Neuropsychopharmacologicum"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib3","article-title":"A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter","author":"Amato","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0893-133X(02)00287-7","article-title":"Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs","volume":"27","author":"Andersson","year":"2002","journal-title":"Neuropsychopharmacology : Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","article-title":"Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey","volume":"2","author":"Anthony","year":"1996","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","article-title":"Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade","volume":"51","author":"Arnt","year":"1982","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(95)00292-S","article-title":"Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine","volume":"283","author":"Arnt","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s007020050142","article-title":"Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors","volume":"106","author":"Ase","year":"1999","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0014-2999(73)90028-9","article-title":"Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol","volume":"22","author":"Asper","year":"1973","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/npp.2011.10","article-title":"Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues","volume":"36","author":"Bedard","year":"2011","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/schbul\/sbs077","article-title":"Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia","volume":"39","author":"Bedard","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0031-6997(24)01509-6","article-title":"Neurotensin and dopamine interactions","volume":"53","author":"Binder","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2005.03.008","article-title":"Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958","volume":"49","author":"Bishop","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/jpet.104.066365","article-title":"Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A\/2C agonism","volume":"310","author":"Bishop","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib16","first-page":"329","article-title":"The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain","volume":"1","author":"Bissette","year":"1988","journal-title":"Neuropsychopharmacology : Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2013.04.058","article-title":"Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers","volume":"435","author":"Borroto-Escuela","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/oxfordjournals.schbul.a006932","article-title":"Review of antipsychotic medication administration: a proposal of intermittent dosing","volume":"28","author":"Boshes","year":"2002","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00023210-200721010-00002","article-title":"Neurotensin agonists: potential in the treatment of schizophrenia","volume":"21","author":"Boules","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cne.21034","article-title":"Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1\/2 map kinase pathway","volume":"498","author":"Brown","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0893-133X(96)00053-X","article-title":"5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia","volume":"15","author":"Burnet","year":"1996","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1126\/science.847477","article-title":"Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain","volume":"196","author":"Burt","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-2999(88)90573-0","article-title":"Scopolamine modulates apomorphine-induced behavior in rats treated with haloperidol or SCH 23390","volume":"148","author":"Butkerait","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410310404","article-title":"Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission","volume":"31","author":"Calabresi","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0304-3940(90)90564-P","article-title":"Thioridazine chronic administration: a behavioural and autoradiographic study","volume":"109","author":"Calza","year":"1990","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/ajp.156.3.412","article-title":"Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks","volume":"156","author":"Carpenter","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1369-1600.2008.00145.x","article-title":"Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors","volume":"14","author":"Carvalho","year":"2009","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(86)90540-6","article-title":"The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity","volume":"120","author":"Carvey","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0920-9964(91)90029-Q","article-title":"Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia","volume":"4","author":"Casey","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0006-3223(98)00029-8","article-title":"Striatal enlargement in rats chronically treated with neuroleptic","volume":"44","author":"Chakos","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib31","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.euroneuro.2015.10.002","article-title":"5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity","volume":"25","author":"Charron","year":"2015","journal-title":"Eur. Neuropsychopharmacol. : J. Eur. College Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib32","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1460-9568.1995.tb01043.x","article-title":"Dopamine autoreceptor sensitivity is unchanged in rat nucleus accumbens after chronic haloperidol treatment: an in vivo and in vitro voltammetric study","volume":"7","author":"Chesi","year":"1995","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment","volume":"5","author":"Chouinard","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.137.1.16","article-title":"Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics","volume":"137","author":"Chouinard","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.135.11.1409","article-title":"Neuroleptic-induced supersensitivity psychosis","volume":"135","author":"Chouinard","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib37","first-page":"891","article-title":"Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients","volume":"22","author":"Chouinard","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0014-2999(80)90438-0","article-title":"Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration","volume":"63","author":"Clow","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-3565(25)23733-8","article-title":"Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens","volume":"248","author":"Compton","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1476-5381.1981.tb16784.x","article-title":"Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment","volume":"73","author":"Dawbarn","year":"1981","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuropharm.2015.03.012","article-title":"Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function","volume":"99","author":"El Hage","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib45","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11874","article-title":"Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study","volume":"79","author":"Emsley","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0773.1996.tb00009.x","article-title":"Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat","volume":"79","author":"Ericson","year":"1996","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/291073a0","article-title":"Neurotensin blocks certain amphetamine-induced behaviours","volume":"291","author":"Ervin","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0269881109359097","article-title":"A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis","volume":"25","author":"Fallon","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2045125311431105","article-title":"Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients","volume":"2","author":"Fallon","year":"2012","journal-title":"Therapeutic Adv. Psychopharmacol."},{"issue":"Suppl. l","key":"10.1016\/j.neuropharm.2019.05.007_bib50","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/BF00442555","article-title":"D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics","volume":"99","author":"Farde","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0006-8993(97)00306-5","article-title":"The effects of intra-accumbens neurotensin on sensorimotor gating","volume":"760","author":"Feifel","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib52","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/0006-2952(83)90397-0","article-title":"Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors","volume":"32","author":"Fleminger","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib53","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1523\/JNEUROSCI.16-06-02020.1996","article-title":"Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus","volume":"16","author":"Flores","year":"1996","journal-title":"J. Neurosci. : Off. J. Soc. Neuroscie.."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib54","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0024-3205(89)90368-8","article-title":"Attenuation of the behavioral response to quisqualic acid and glutamic acid diethyl ester by chronic haloperidol administration","volume":"44","author":"Freed","year":"1989","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0197-0186(88)90145-3","article-title":"Neurotensin concentrations in rat striatum and nucleus accumbens: further studies of their regulation","volume":"12","author":"Frey","year":"1988","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainresbull.2008.05.004","article-title":"Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice","volume":"77","author":"Fukushiro","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0447.1994.tb05863.x","article-title":"Intermittent medication--an alternative?","volume":"382","author":"Gaebel","year":"1994","journal-title":"Acta psychiatrica Scandinavica Supplementum"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-9964(01)00182-7","article-title":"First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies","volume":"53","author":"Gaebel","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/schbul\/sbt236","article-title":"Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia","volume":"40","author":"Gill","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","author":"Ginovart","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib61","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/npp.2008.116","article-title":"D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats","volume":"34","author":"Ginovart","year":"2009","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib62","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(85)90488-3","article-title":"The effects of chronic neuroleptic treatment on neurotensin-like immunoreactivity in the rat central nervous system","volume":"335","author":"Goedert","year":"1985","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3565(25)32314-1","article-title":"Increase of neurotensin content elicited by neuroleptics in nucleus accumbens","volume":"215","author":"Govoni","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib64","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/npp.2008.199","article-title":"The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study","volume":"34","author":"Graff-Guerrero","year":"2009","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib65","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF00451692","article-title":"Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics","volume":"98","author":"Halperin","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib66","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1023231611616","article-title":"Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs","volume":"28","author":"Hanaoka","year":"2003","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib67","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-3565(25)10934-8","article-title":"Enhanced sensitivity to the behavioral effects of cocaine after chronic administration of D2-selective dopamine antagonists in the squirrel monkey","volume":"262","author":"Howell","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib69","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0197-0186(96)00093-9","article-title":"Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies","volume":"30","author":"Huang","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0006-8993(90)90532-G","article-title":"Apomorphine does not reverse reduced basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment","volume":"507","author":"Ichikawa","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0006-8993(92)90805-J","article-title":"The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo","volume":"574","author":"Ichikawa","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib74","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0b013e31828ea95c","article-title":"Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis","volume":"33","author":"Iyo","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","article-title":"Glutamate and schizophrenia: phencyclidine, N\u2010methyl\u2010d\u2010aspartate receptors, and dopamine\u2013glutamate interactions","volume":"78","author":"Javitt","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib76","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0022-3565(25)13222-9","article-title":"One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists","volume":"253","author":"Jiang","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib77","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0306-4522(94)90568-1","article-title":"Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain","volume":"63","author":"Johnson","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib78","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00002018-199308050-00001","article-title":"Continuous versus intermittent neuroleptic therapy in schizophrenia","volume":"8","author":"Jolley","year":"1993","journal-title":"Drug Saf."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib79","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/bmj.301.6756.837","article-title":"Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years","volume":"301","author":"Jolley","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib80","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0306-4522(84)90203-3","article-title":"Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing","volume":"11","author":"Kalivas","year":"1984","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib81","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib83","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008877-200109000-00007","article-title":"Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings","volume":"12","author":"Kestler","year":"2001","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib85","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1176\/ajp.142.11.1259","article-title":"The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence","volume":"142","author":"Khantzian","year":"1985","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib86","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/0006-2952(88)90017-2","article-title":"Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei","volume":"37","author":"Kilts","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-3565(24)38870-6","article-title":"Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain","volume":"295","author":"Kinkead","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib88","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1523\/JNEUROSCI.1120-05.2005","article-title":"Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs","volume":"25","author":"Kippin","year":"2005","journal-title":"J. Neurosci. : Off. J. Soc. Neuroscie."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib89","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/cn200020y","article-title":"Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics","volume":"2","author":"Koschatzky","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/schbul\/23.2.203","article-title":"Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats","volume":"23","author":"Kosten","year":"1997","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib91","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0091-3057(81)90241-0","article-title":"Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses","volume":"14","author":"Kuribara","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.npp.1301110","article-title":"Time course of the antipsychotic effect and the underlying behavioral mechanisms","volume":"32","author":"Li","year":"2007","journal-title":"Neuropsychopharmacology : Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF01276508","article-title":"Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study","volume":"102","author":"Li","year":"1995","journal-title":"J. Neural Transm. Gen. Sect."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib94","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib95","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0091-3057(85)90025-5","article-title":"A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs","volume":"23","author":"Ljungberg","year":"1985","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib96","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1345\/aph.1A440","article-title":"Metoclopramide-induced supersensitivity psychosis","volume":"36","author":"Lu","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(85)90732-0","article-title":"Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum","volume":"113","author":"MacKenzie","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib98","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejn.12401","article-title":"Estrogen potentiates the behavioral and nucleus accumbens dopamine response to continuous haloperidol treatment in female rats","volume":"39","author":"Madularu","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.yhbeh.2016.04.007","article-title":"High estrogen and chronic haloperidol lead to greater amphetamine-induced BOLD activation in awake, amphetamine-sensitized female rats","volume":"82","author":"Madularu","year":"2016","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","article-title":"D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib101","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0014-2999(93)90448-Q","article-title":"Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation","volume":"231","author":"Marin","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-2999(96)00910-7","article-title":"Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain","volume":"318","author":"McCoy","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib103","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1192\/bjp.137.6.510","article-title":"Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia","volume":"137","author":"McCreadie","year":"1980","journal-title":"Br. J. Psychiatry : J. Ment. Sci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib104","first-page":"390","article-title":"The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-328X(98)00196-X","article-title":"Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats","volume":"61","author":"Meng","year":"1998","journal-title":"Brain research Molecular brain research"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib106","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1523\/JNEUROSCI.12-02-00652.1992","article-title":"Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum","volume":"12","author":"Merchant","year":"1992","journal-title":"J. Neurosci. : Off. J. Soc. Neuroscie."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib107","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-3565(25)22817-8","article-title":"Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions","volume":"271","author":"Merchant","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib108","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1046\/j.1471-4159.1996.67051965.x","article-title":"Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses","volume":"67","author":"Meshul","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib109","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00421933","article-title":"Pharmacology of neuroleptics upon repeated administration","volume":"34","author":"M\u00d8ller Nielsen","year":"1974","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","article-title":"Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse","volume":"114","author":"Moncrieff","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib111","first-page":"401","article-title":"Behavioral supersensitivity to methamphetamine following chronic treatment with (--)-sulpiride in the rat","volume":"57","author":"Montanaro","year":"1981","journal-title":"Bollettino della Societa italiana di biologia sperimentale"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(82)90595-7","article-title":"Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol","volume":"81","author":"Montanaro","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib113","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib114","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br. J. Psychiatry : J. Ment. Sci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0006-8993(92)90098-T","article-title":"Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment","volume":"575","author":"Myers","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib116","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib117","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib118","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/syn.890060205","article-title":"Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain","volume":"6","author":"O'Dell","year":"1990","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-2999(99)00666-4","article-title":"Differential behavioural effect of quinpirole in neuroleptic-pretreated rats - role of alpha(1)-adrenoceptor","volume":"384","author":"Obuchowicz","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib120","first-page":"1845","article-title":"Genetic association between G protein-coupled receptor kinase 6\/beta-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia","volume":"11","author":"Oda","year":"2015","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib121","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0269881115593903","article-title":"G protein-coupled receptor kinase 6\/beta-arrestin 2 system in a rat model of dopamine supersensitivity psychosis","volume":"29","author":"Oda","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib122","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1007\/s00213-017-4695-5","article-title":"Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats","volume":"234","author":"Oda","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib123","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib124","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0014-2999(95)00619-2","article-title":"The subsensitivity of striatal glutamate receptors induced by chronic haloperidol in rats","volume":"294","author":"Ossowska","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2019.05.007_bib125","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/0924-977X(96)00011-9","article-title":"Proper psychosocial rehabilitation for stabilised patients with schizophrenia: the role of new therapies","volume":"6","author":"Peuskens","year":"1996","journal-title":"Eur. Neuropsychopharmacol. : J. Eur. College Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib126","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0306-4522(91)90234-F","article-title":"Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding","volume":"45","author":"Pierce","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib127","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(01)00333-5","article-title":"5-HT2A and 5-HT2C\/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum","volume":"26","author":"Porras","year":"2002","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib128","first-page":"61","article-title":"Nitric oxide synthesis inhibition attenuates haloperidol-induced supersensitivity","volume":"22","author":"Pudiak","year":"1997","journal-title":"J. Psychiatry Neurosci. : JPN"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00432771","article-title":"Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol","volume":"77","author":"Rebec","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/01.jcp.0000185341.55096.65","article-title":"Extended\" antipsychotic dosing: rationale and pilot data","volume":"25","author":"Remington","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib131","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.09m05866yel","article-title":"Extended\" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial","volume":"72","author":"Remington","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib132","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","article-title":"A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone","volume":"163","author":"Remington","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib133","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib134","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/BF00207247","article-title":"The effect of haloperidol on cocaine self-administration is augmented with repeated administrations","volume":"93","author":"Roberts","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-8993(93)90808-Z","article-title":"Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat","volume":"622","author":"Robledo","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib136","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1098-2396(19990915)33:4<289::AID-SYN6>3.0.CO;2-I","article-title":"Enhancement of N-methyl-D-aspartate (NMDA) immunoreactivity in residual dendritic spines in the caudate-putamen nucleus after chronic haloperidol administration","volume":"33","author":"Rodriguez","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib137","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1345\/aph.1Q214","article-title":"Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia","volume":"45","author":"Roy-Desruisseaux","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pnpbp.2013.06.008","article-title":"Can antipsychotic treatment contribute to drug addiction in schizophrenia?","volume":"52","author":"Samaha","year":"2014","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib139","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"Breakthrough\" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J. Neurosci. : Off. J. Soc. Neuroscie."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biopsych.2008.01.010","article-title":"Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery","volume":"64","author":"Samaha","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib141","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/S0024-3205(02)01535-7","article-title":"Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats","volume":"70","author":"Scarr","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib142","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00005053-198711000-00001","article-title":"A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice","volume":"175","author":"Schneier","year":"1987","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib143","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/schbul\/17.2.311","article-title":"Maintenance medication for schizophrenia: strategies for dose reduction","volume":"17","author":"Schooler","year":"1991","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib144","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0304-3940(92)90629-L","article-title":"Changes in striatal dopamine release and metabolism during and after subchronic haloperidol administration in rats","volume":"142","author":"See","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0006-8993(95)01114-5","article-title":"Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats","volume":"704","author":"See","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib146","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/syn.20498","article-title":"Dopamine D2(High) receptors moderately elevated by sertindole","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib147","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/syn.20557","article-title":"Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib148","article-title":"Yes, Breast is best but taper domperidone when stopping (e-letter)","author":"Seeman","year":"2014","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib149","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","article-title":"Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors","volume":"16","author":"Seeman","year":"1997","journal-title":"Neuropsychopharmacology : Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib150","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib151","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1073\/pnas.0409766102","article-title":"Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis","volume":"102","author":"Seeman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib152","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2017.05.015","article-title":"Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment","volume":"123","author":"Servonnet","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib153","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00432038","article-title":"Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug","volume":"84","author":"Severson","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib154","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib1a","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/070674370204700710","article-title":"Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence","volume":"47","author":"Smelson","year":"2002","journal-title":"Can. J. Psychiatr. Rev. Canad. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib2a","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.jcp.0000194624.07611.5e","article-title":"The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report","volume":"26","author":"Smelson","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib155","first-page":"285","article-title":"Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment","volume":"1","author":"Smith","year":"1975","journal-title":"Psychopharmacol. Commun."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.neuropharm.2004.04.020","article-title":"The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors","volume":"47","author":"Steward","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib157","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib158","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/schbul\/sbr006","article-title":"Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis","volume":"38","author":"Tadokoro","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib159","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0269881112439252","article-title":"Examining the effectiveness of antipsychotic medication in first-episode psychosis","volume":"26","author":"Taylor","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib160","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.comppsych.2007.05.003","article-title":"Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study","volume":"48","author":"Tenback","year":"2007","journal-title":"Compr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib161","doi-asserted-by":"crossref","first-page":"9174","DOI":"10.1074\/jbc.M110.166454","article-title":"Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism","volume":"286","author":"Thibault","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib162","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2015.03.025","article-title":"Challenging the need for sustained blockade of dopamine D(2) receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: a single-blind, randomized, controlled study","volume":"164","author":"Tsuboi","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib163","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/sj.npp.1300233","article-title":"Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats","volume":"28","author":"Turrone","year":"2003","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib164","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","article-title":"The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats","volume":"165","author":"Turrone","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.biopsych.2004.10.023","article-title":"Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats","volume":"57","author":"Turrone","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib166","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/JCP.0000000000000065","article-title":"Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications","volume":"34","author":"Uchida","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib167","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib168","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/070674370705200704","article-title":"Geographical variation in the prevalence of problematic substance use in Canada","volume":"52","author":"Veldhuizen","year":"2007","journal-title":"Canadian journal of psychiatry Revue canadienne de psychiatrie"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib169","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0304-3940(90)90016-3","article-title":"Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen","volume":"109","author":"von Euler","year":"1990","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(25)30124-2","article-title":"Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment","volume":"193","author":"Vonvoigtlander","year":"1975","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib171","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","article-title":"The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?","volume":"23","author":"Wadenberg","year":"1999","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib172","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology Off. Pub. Am. Coll. Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib173","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002130000466","article-title":"Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats","volume":"150","author":"Wadenberg","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib174","volume":"vol. 3","author":"Waln","year":"2013"},{"key":"10.1016\/j.neuropharm.2019.05.007_bib175","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0006-8993(89)90833-0","article-title":"Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain","volume":"487","author":"Wilmot","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib176","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00004714-199102000-00005","article-title":"The prevalence of tardive dyskinesia","volume":"11","author":"Woerner","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib177","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0006-8993(00)02080-1","article-title":"Enhanced accumbal dopamine release following 5-HT(2A) receptor stimulation in rats pretreated with intermittent cocaine","volume":"863","author":"Yan","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.007_bib178","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.schres.2014.01.017","article-title":"Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data","volume":"153","author":"Yoshida","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:57:42Z","timestamp":1758437862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819301571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":180,"alternative-id":["S0028390819301571"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.007","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic-evoked dopamine supersensitivity","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107630"}}